Global University Venturing

Based on research at University of Adelaide, Royal Adelaide Hospital and Johns Hopkins's Hospital, Glyscend is working on a pill to treat type 2 diabetes.

UCeed will target four to eight healthcare projects with a focus on child medicine, investing up to $220,000 per transaction.

OHSU's CNS disorder drug developer has launched with $76m from investors co-led by Arch Venture Partners and Cowen Healthcare Investments.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Stanford’s lysosome protein degradation spinout Lycia emerged with $50m of capital from Versant Ventures to develop a portfolio of drug candidates.

Mercia Asset Management has lost its investment director and university lead Nicola Broughton to a new $171m fund targeting the medical cannabis industry.

Existing backer GV returned to take part in a $100m round for the Stanford spinout that also attracted new investor Regeneron Pharmaceuticals.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Varian Medical Systems and Johnson & Johnson Innovation – JJDC have returned for the series C-1 round having backed the U-M spinout's series C last year.

Christophe Haunold has departed Institut national polytechnique de Toulouse to head up a new tech transfer office launched by University of Luxembourg.

Eli Lilly will collaborate on five drug candidates based on the Oxford and Karolinska Institute spinout's exosome delivery technology.